Incorporating data from 34,322 patients in EMPA-REG OUTCOME, CANVAS and DECLARE-TIMI 58, the clinical benefits of SGLT2 inhibitors are in reducing the risk of a 3-point MACE (MI, stroke or cardiovascular death) only in those with established CVD (HR 0.86; 95% CI 0.80, 0.93) and not in those with multiple risk factors (HR 1.00; 95% CI 0.87, 1.16) (Figure 3). The gene discussed is SLC5A2; the disease is stroke disorder.